Cannabidiol (CBD): Implicit, Unsubstantiated Therapeutic Claims through Academic Joint Ventures in an Unregulated Marketplace Could Risk Public Health
Executive Summary: Cannabidiol (CBD) use has increased recently, owing in part to the declassification of hemp from the Controlled Substances Act (CSA) in 2018. Despite a Food and Drug Administration (FDA)-approved CBD prescription drug product for the treatment of some epileptic seizures, a direct-to-consumer market has also emerged, which lacks sufficient regulatory oversight. The National Consumers League (NCL) studied the CBD direct-to-consumer market landscape, including the “research as marketing” phenomenon, and compiled its findings into this white paper. With the FDA taking enforcement action against companies making explicit health treatment claims, other entities are turning to partnerships with academia to further investigate CBD’s therapeutic potential. Some companies appear to be leveraging these partnerships as “research as marketing,”1 which could potentially mislead the consumer and risk public health.
For complete article go to Consumers of Safe CBD